View ValuationPaxman 将来の成長Future 基準チェック /66Paxman利益と収益がそれぞれ年間57.2%と30.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に41.8% 57.3%なると予測されています。主要情報57.2%収益成長率57.32%EPS成長率Medical Equipment 収益成長16.4%収益成長率30.1%将来の株主資本利益率41.75%アナリストカバレッジLow最終更新日26 Feb 2024今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 23+ 1 more updatePaxman AB (publ) to Report First Half, 2026 Results on Aug 21, 2026Paxman AB (publ) announced that they will report first half, 2026 results on Aug 21, 2026お知らせ • May 20Paxman AB (publ) to Report Q1, 2026 Results on May 21, 2026Paxman AB (publ) announced that they will report Q1, 2026 results at 7:00 AM, Central European Standard Time on May 21, 2026お知らせ • Apr 21Paxman AB (publ), Annual General Meeting, May 22, 2026Paxman AB (publ), Annual General Meeting, May 22, 2026, at 10:00 W. Europe Standard Time. Location: minnesota conference venue, pirgatan 6, 374 35 karlshamn, sweden, Swedenお知らせ • Feb 23Paxman AB (publ) to Report Fiscal Year 2025 Results on Feb 27, 2026Paxman AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 27, 2026お知らせ • Feb 21Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral NeuropathyPaxman announced that the American Medical Association (AMA) CPT Editorial Panel has established three Category III CPT®? codes describing the use of the Paxman Cryocompression Device for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in hands and feet. Taking effect January 1, 2027, the new Category III codes establish a standardized reporting pathway for mechanical extremity cryocompression therapy delivered in conjunction with neurotoxic chemotherapy: The three-code structure mirrors the established coding framework for Paxman's FDA-cleared scalp cooling system, supporting structured reporting, data collection, and payer engagement. During chemotherapy infusion, The Paxman Neuropathy System combines consistent cooling and dynamic compression to the hands and feet to reduce the incidence and severity of CIPN - a common side effect of widely used chemotherapies such as paclitaxel and docetaxel, that can significantly impair patients' quality of life. In October, The Paxman Neuropathy system was accepted into the U.S. Food and Drug Administration Safer Technologies Program (STeP), a voluntary program designed to facilitate development and review of medical devices expected to improve safety outcomes. The device is currently under substantive review by the FDA. Product launches in select markets are planned for 2026, with launch to all markets anticipated in 2027. Clinical development of The Paxman Neuropathy System is supported by strong and expanding evidence, including ongoing clinical trials conducted by the SWOG Cancer Research Network, Dana-Farber Cancer Institute, and the National University Hospital Singapore. Together, these studies are contributing to a growing global evidence base evaluating the safety and effectiveness of cryocompression therapy in preventing CIPN.お知らせ • Jan 02Paxman Announces 510k Submission to the U.S. Food and Drug Administration for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral NeuropathyPAXMAN announced that the U.S. Food and Drug Administration (FDA) has confirmed receipt of the 510k Submission for the Paxman cryocompression device to prevent chemotherapy-induced peripheral neuropathy (CIPN). A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective. This follows the news in October, that the Paxman device, was accepted into the US FDA's Safer Technologies Program (STeP), and additionally, confirmation that the Category III CPT Code Application for the device, submitted to the American Medical Association (AMA) in November, is to be included on the Proposed Agenda for the February 2026 CPT®? Editorial Panel Meeting. These steps mark significant milestones in Paxman's regulatory pathways towards FDA clearance of this new technology. Product launches in select markets are currently being planned for 2026 with launch to all markets anticipated in 2027. More information regarding timelines will be communicated in the New Year.お知らせ • Oct 20PAXMAN Announces Acceptance of Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies ProgramPAXMAN announced that the U.S. Food and Drug Administration (FDA) has accepted the Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies Program (STeP). The FDA's Safer Technologies Program ("STeP") is a voluntary initiative designed to accelerate the development and clearance of medical devices that have the potential to reduce known risks associated with current treatments for non-life threatening conditions. Paxman submitted the STeP Designation Request Q240974/S002 in August 2025. Confirmation that the PLCS meets the eligibility factors for STeP is a significant milestone in Paxman's regulatory pathways towards FDA clearance of this new technology. Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting toxicity of paclitaxel and docetaxel, which are both widely used drugs for the treatment of common cancers including breast, ovarian, endometrial, lung, and gastric cancers. CIPN is an unseen, debilitating, and lifelong condition that severely impacts the quality of life of cancer patients. Acceptance into STeP underscores the innovative potential of the Paxman device to address this important unmet clinical need of reducing the incidence and severity of CIPN in cancer patients receiving systemic neurotoxic chemotherapy or combination therapy.お知らせ • Apr 17Paxman AB (publ), Annual General Meeting, May 16, 2025Paxman AB (publ), Annual General Meeting, May 16, 2025, at 10:00 W. Europe Standard Time. Location: at meeting hall zambesi, netport, biblioteksgatan 4, karlshamn, Swedenお知らせ • Apr 08Paxman AB (Publ) Elects Peter Mattisson as ChairmanPaxman AB (publ) announced that Company held its Extra General Meeting on 8 April 2025 in Karlshamn. At the meeting, Peter Mattisson was elected Chairman.お知らせ • Mar 22Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million.Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,900,000 Price\Range: SEK 65 Transaction Features: Subsequent Direct Listingお知らせ • Mar 21Paxman AB (publ) has filed a Follow-on Equity Offering.Paxman AB (publ) has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 1,900,000 Transaction Features: Subsequent Direct Listingお知らせ • Mar 19Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc and others for Approximately SEK 150 million.Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc. and others for Approximately SEK 150 million on March 18, 2025. As part of acquisition, Paxman AB will acquire all shares in Dignitana AB. As part of consideration, Paxman AB will issue 2.5 million newly issued shares at a ratio of 0.030744 per common equity of Dignitana AB (publ). The merger between Paxman and Dignitana creates a New Group which provides clear synergies through increased revenues and reduced costs through rationalization but also economies of scale. Upon completion of the Offer, the shareholders of Paxman will own approximately 88.5% of the votes and capital and the shareholders of Dignitana will own approximately 11.5% of the votes and capital of the New Group. Agartha AB, which controls approximately 29.8% of the total number of outstanding shares and votes in Dignitana, supports and has undertaken to accept the Offer. The acceptance period for the Offer is expected to commence on or around April 14, 2025 and end on or around May 5, 2025, with payment of consideration expected to be made on or around May 13, 2025. In the event that Paxman, in connection with the Offer or otherwise, becomes the owner of shares corresponding to more than 90% of the shares in Dignitana, Paxman intends to call for compulsory acquisition in accordance with the Swedish Companies Act (2005:551) in order to acquire all outstanding shares in Dignitana. In connection therewith, Paxman intends to promote the delisting of Dignitana's shares from Nasdaq First North. The transaction is subject to Offer being accepted to the extent that Paxman becomes the owner of the equivalent of more than 90% of all outstanding shares in Dignitana, approval of the shareholders of Paxman at the extraordinary general meeting of Paxman AB, all necessary authorizations, approvals, decisions and other measures for the Offer and the acquisition of Dignitana are obtained on terms acceptable to Paxman, including approvals from the Inspectorate of Strategic Products and the corresponding authorities in the United Kingdom and Italy. The Offer has been preceded by Paxman conducting a limited due diligence review of Dignitana of a confirmatory nature. The expected completion of the transaction is May 5, 2025. Advokatfirman Delphi KB acted as legal advisor to Paxman AB. Bergs Securities AB acted as financial advisor and issuing agent to Paxman AB. Advokatfirman Vinge KB act as legal advisor to Dignitana AB. Stockholm Corporate Finance AB act as financial advisor to Dignitana AB.お知らせ • Feb 21+ 3 more updatesPaxman AB (publ) to Report Nine Months, 2025 Results on Nov 14, 2025Paxman AB (publ) announced that they will report nine months, 2025 results on Nov 14, 2025お知らせ • May 24Paxman AB (publ) Appoints Karen Giddings Clakely to the BoardPAXMAN´s AGM held on 23 May 2024, appointed Karen Giddings Clakely to the board.お知らせ • Aug 31+ 4 more updatesPaxman AB (publ) to Report First Half, 2024 Results on Aug 21, 2024Paxman AB (publ) announced that they will report first half, 2024 results on Aug 21, 2024お知らせ • Jan 04Paxman AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023Paxman AB (publ) announced that they will report fiscal year 2022 results on May 04, 2023業績と収益の成長予測OTCPK:PXMB.F - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202653712376102112/31/2025401845578112/31/202429234315013/31/202423624128N/A12/31/20232218-1016N/A9/30/20232081-288N/A6/30/2023188-2-315N/A3/31/2023173-7-384N/A12/31/2022157-10-333N/A9/30/2022143-2-204N/A6/30/2022125-12-168N/A3/31/2022111-18-27-3N/A12/31/2021105-13-28-4N/A9/30/202193-23-14-7N/A6/30/202187-21-19-12N/A3/31/202180-22-16-9N/A12/31/202083-19-15-8N/A9/30/202090-6-22-1N/A6/30/202096-1-182N/A3/31/20201026-152N/A12/31/2019963-183N/A9/30/201990-4-7-1N/A6/30/201983-5-190N/A3/31/201975-6-182N/A12/31/201869-7-180N/A9/30/201858-9-241N/A6/30/201850-10-20-7N/A3/31/201843-9-25-8N/A12/31/201736-7N/A-7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PXMB.Fの予測収益成長率 (年間57.2% ) は 貯蓄率 ( 2.5% ) を上回っています。収益対市場: PXMB.Fの収益 ( 57.2% ) はUS市場 ( 18.1% ) よりも速いペースで成長すると予測されています。高成長収益: PXMB.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: PXMB.Fの収益 ( 30.1% ) US市場 ( 12.8% ) よりも速いペースで成長すると予測されています。高い収益成長: PXMB.Fの収益 ( 30.1% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PXMB.Fの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 41.8 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/13 10:56終値2024/05/16 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Paxman AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Maria Karlsson OsipovaDNB Carnegie Commissioned ResearchLudvig SvenssonDNB Carnegie Commissioned ResearchGustaf MeyerRedeye
お知らせ • May 23+ 1 more updatePaxman AB (publ) to Report First Half, 2026 Results on Aug 21, 2026Paxman AB (publ) announced that they will report first half, 2026 results on Aug 21, 2026
お知らせ • May 20Paxman AB (publ) to Report Q1, 2026 Results on May 21, 2026Paxman AB (publ) announced that they will report Q1, 2026 results at 7:00 AM, Central European Standard Time on May 21, 2026
お知らせ • Apr 21Paxman AB (publ), Annual General Meeting, May 22, 2026Paxman AB (publ), Annual General Meeting, May 22, 2026, at 10:00 W. Europe Standard Time. Location: minnesota conference venue, pirgatan 6, 374 35 karlshamn, sweden, Sweden
お知らせ • Feb 23Paxman AB (publ) to Report Fiscal Year 2025 Results on Feb 27, 2026Paxman AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 27, 2026
お知らせ • Feb 21Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral NeuropathyPaxman announced that the American Medical Association (AMA) CPT Editorial Panel has established three Category III CPT®? codes describing the use of the Paxman Cryocompression Device for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in hands and feet. Taking effect January 1, 2027, the new Category III codes establish a standardized reporting pathway for mechanical extremity cryocompression therapy delivered in conjunction with neurotoxic chemotherapy: The three-code structure mirrors the established coding framework for Paxman's FDA-cleared scalp cooling system, supporting structured reporting, data collection, and payer engagement. During chemotherapy infusion, The Paxman Neuropathy System combines consistent cooling and dynamic compression to the hands and feet to reduce the incidence and severity of CIPN - a common side effect of widely used chemotherapies such as paclitaxel and docetaxel, that can significantly impair patients' quality of life. In October, The Paxman Neuropathy system was accepted into the U.S. Food and Drug Administration Safer Technologies Program (STeP), a voluntary program designed to facilitate development and review of medical devices expected to improve safety outcomes. The device is currently under substantive review by the FDA. Product launches in select markets are planned for 2026, with launch to all markets anticipated in 2027. Clinical development of The Paxman Neuropathy System is supported by strong and expanding evidence, including ongoing clinical trials conducted by the SWOG Cancer Research Network, Dana-Farber Cancer Institute, and the National University Hospital Singapore. Together, these studies are contributing to a growing global evidence base evaluating the safety and effectiveness of cryocompression therapy in preventing CIPN.
お知らせ • Jan 02Paxman Announces 510k Submission to the U.S. Food and Drug Administration for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral NeuropathyPAXMAN announced that the U.S. Food and Drug Administration (FDA) has confirmed receipt of the 510k Submission for the Paxman cryocompression device to prevent chemotherapy-induced peripheral neuropathy (CIPN). A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective. This follows the news in October, that the Paxman device, was accepted into the US FDA's Safer Technologies Program (STeP), and additionally, confirmation that the Category III CPT Code Application for the device, submitted to the American Medical Association (AMA) in November, is to be included on the Proposed Agenda for the February 2026 CPT®? Editorial Panel Meeting. These steps mark significant milestones in Paxman's regulatory pathways towards FDA clearance of this new technology. Product launches in select markets are currently being planned for 2026 with launch to all markets anticipated in 2027. More information regarding timelines will be communicated in the New Year.
お知らせ • Oct 20PAXMAN Announces Acceptance of Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies ProgramPAXMAN announced that the U.S. Food and Drug Administration (FDA) has accepted the Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies Program (STeP). The FDA's Safer Technologies Program ("STeP") is a voluntary initiative designed to accelerate the development and clearance of medical devices that have the potential to reduce known risks associated with current treatments for non-life threatening conditions. Paxman submitted the STeP Designation Request Q240974/S002 in August 2025. Confirmation that the PLCS meets the eligibility factors for STeP is a significant milestone in Paxman's regulatory pathways towards FDA clearance of this new technology. Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting toxicity of paclitaxel and docetaxel, which are both widely used drugs for the treatment of common cancers including breast, ovarian, endometrial, lung, and gastric cancers. CIPN is an unseen, debilitating, and lifelong condition that severely impacts the quality of life of cancer patients. Acceptance into STeP underscores the innovative potential of the Paxman device to address this important unmet clinical need of reducing the incidence and severity of CIPN in cancer patients receiving systemic neurotoxic chemotherapy or combination therapy.
お知らせ • Apr 17Paxman AB (publ), Annual General Meeting, May 16, 2025Paxman AB (publ), Annual General Meeting, May 16, 2025, at 10:00 W. Europe Standard Time. Location: at meeting hall zambesi, netport, biblioteksgatan 4, karlshamn, Sweden
お知らせ • Apr 08Paxman AB (Publ) Elects Peter Mattisson as ChairmanPaxman AB (publ) announced that Company held its Extra General Meeting on 8 April 2025 in Karlshamn. At the meeting, Peter Mattisson was elected Chairman.
お知らせ • Mar 22Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million.Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,900,000 Price\Range: SEK 65 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 21Paxman AB (publ) has filed a Follow-on Equity Offering.Paxman AB (publ) has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 1,900,000 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 19Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc and others for Approximately SEK 150 million.Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc. and others for Approximately SEK 150 million on March 18, 2025. As part of acquisition, Paxman AB will acquire all shares in Dignitana AB. As part of consideration, Paxman AB will issue 2.5 million newly issued shares at a ratio of 0.030744 per common equity of Dignitana AB (publ). The merger between Paxman and Dignitana creates a New Group which provides clear synergies through increased revenues and reduced costs through rationalization but also economies of scale. Upon completion of the Offer, the shareholders of Paxman will own approximately 88.5% of the votes and capital and the shareholders of Dignitana will own approximately 11.5% of the votes and capital of the New Group. Agartha AB, which controls approximately 29.8% of the total number of outstanding shares and votes in Dignitana, supports and has undertaken to accept the Offer. The acceptance period for the Offer is expected to commence on or around April 14, 2025 and end on or around May 5, 2025, with payment of consideration expected to be made on or around May 13, 2025. In the event that Paxman, in connection with the Offer or otherwise, becomes the owner of shares corresponding to more than 90% of the shares in Dignitana, Paxman intends to call for compulsory acquisition in accordance with the Swedish Companies Act (2005:551) in order to acquire all outstanding shares in Dignitana. In connection therewith, Paxman intends to promote the delisting of Dignitana's shares from Nasdaq First North. The transaction is subject to Offer being accepted to the extent that Paxman becomes the owner of the equivalent of more than 90% of all outstanding shares in Dignitana, approval of the shareholders of Paxman at the extraordinary general meeting of Paxman AB, all necessary authorizations, approvals, decisions and other measures for the Offer and the acquisition of Dignitana are obtained on terms acceptable to Paxman, including approvals from the Inspectorate of Strategic Products and the corresponding authorities in the United Kingdom and Italy. The Offer has been preceded by Paxman conducting a limited due diligence review of Dignitana of a confirmatory nature. The expected completion of the transaction is May 5, 2025. Advokatfirman Delphi KB acted as legal advisor to Paxman AB. Bergs Securities AB acted as financial advisor and issuing agent to Paxman AB. Advokatfirman Vinge KB act as legal advisor to Dignitana AB. Stockholm Corporate Finance AB act as financial advisor to Dignitana AB.
お知らせ • Feb 21+ 3 more updatesPaxman AB (publ) to Report Nine Months, 2025 Results on Nov 14, 2025Paxman AB (publ) announced that they will report nine months, 2025 results on Nov 14, 2025
お知らせ • May 24Paxman AB (publ) Appoints Karen Giddings Clakely to the BoardPAXMAN´s AGM held on 23 May 2024, appointed Karen Giddings Clakely to the board.
お知らせ • Aug 31+ 4 more updatesPaxman AB (publ) to Report First Half, 2024 Results on Aug 21, 2024Paxman AB (publ) announced that they will report first half, 2024 results on Aug 21, 2024
お知らせ • Jan 04Paxman AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023Paxman AB (publ) announced that they will report fiscal year 2022 results on May 04, 2023